{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'records to the sponsor. The investigator shall notify the sponsor of any accidental loss or', 'destruction of study records.', '111']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '14.', 'FINANCING AND INSURANCE', 'A separate clinical study agreement, including a study budget, will be signed between each', 'principal investigator and Syneos Health before the IMP is delivered.', 'This clinical study is insured in accordance with applicable legal provisions. The policy coverage', 'is subject to the full policy terms, conditions, extensions, and exclusions. Excluded from the', 'insurance coverage are inter alia, damages to health, and worsening of previous existing disease', 'that would have occurred or continued if the patient had not taken part in the clinical study.', 'The policy of Clinical Trials Insurance will be provided to the investigational centers by the', 'sponsor.', 'For covered clinical studies (see 21CFR54), the investigator will provide the sponsor with', 'financial information required to complete FDA 3454 form. Each investigator will notify the', 'sponsor of any relevant changes during the conduct of the study and for 1 year after the study has', 'been completed.', '112']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '15.', 'REPORTING AND PUBLICATION OF RESULTS', 'The sponsor is responsible for ensuring that the public has access to the appropriate information', 'about the study by conforming to national, local, and regional requirements and regulations for', 'registration and posting of results.', 'The sponsor is responsible for the preparation of a clinical study report in cooperation with the', 'coordinating investigator. The final report is signed by the sponsor and, if applicable, by the', 'coordinating investigator.', 'When the sponsor generates reports from the data collected in this study for presentation to', 'competent authorities, drafts may be circulated to the principal investigator for comments and', 'suggestions. An endorsement of the final report will be sought from the principal investigator.', 'All unpublished information given to the investigator by the sponsor shall not be published or', 'disclosed to a third party without the prior written consent of the sponsor. The primary', 'publication from this study will report the results of the study in accordance with the', '\"Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in', 'Medical Journals\" (www.ICMJE.org). Publication of the results will occur in a timely manner', 'according to applicable regulations. Authorship will be based on meeting all the following', '4 criteria:', 'substantial contributions to the conception or design of the work; or the acquisition,', 'analysis, or interpretation of data for the work', 'drafting the work or revising it critically for important intellectual content', 'final approval of the version to be published', 'agreement to be accountable for all aspects of the work in ensuring that questions', 'related to the accuracy or integrity of any part of the work are appropriately', 'investigated and resolved', 'The publications committee established by the sponsor will oversee this process. Additional', 'publications may follow. Policies regarding the publication of the study results are defined in the', 'financial agreement.', 'No patent applications based on the results of the study may be made by the investigator nor may', 'assistance be given to any third party to make such an application without the written', 'authorization of the sponsor.', '113']\n\n###\n\n", "completion": "END"}